Allergy Asthma Associates

Europrevall

|

|

|

Global Trials (Multicentric Multinational)

Study Phase And Duration	Indication	Subject Allotted	Time Allotted	Recruitment Time taken	Patient Enrollment Details
Study Phase And Duration	Indication	Subject Allotted	Time Allotted	Recruitment Time taken	Screened	Randomized	Completed
Phase III 54 weeks	COPD	20	8 weeks	4 weeks	30	19	10
Phase III 53 weeks	Rhinitis	15	24 weeks	12 weeks	24	21	18
Phase II 12 weeks	Asthma	05	1 week	1 week	10	0	Early termination globally as per sponsor
Phase II 12 weeks	Asthma	30	24 weeks	24 weeks	94	45	42
Phase II 12 weeks	Asthma	25	28 weeks	28 weeks	69	33	27
Phase III 54 weeks	COPD	10	24 Weeks	24 Weeks	40	09	Ongoing
Phase III 54 weeks	COPD	10	24 Weeks	12 Weeks	22	19	Ongoing
Phase III 54 weeks	Asthma	06	2 Weeks	2 Weeks	08	05	Ongoing
Phase II 2 weeks	Asthma	05	12 Weeks	12 Weeks	16	01	00
Phase III 54 weeks	Asthma	30	24 Weeks	24 Weeks	20	04	Ongoing

Indian Trials (Multicentric)

Study Phase	Indication	Subject Allotted	Time Allotted	Recruitment Time	Patient Enrollment Details
Study Phase	Indication	Subject Allotted	Time Allotted	Recruitment Time	Screened	Randomized	Completed
Phase II 24 weeks	Asthma	36	24 weeks	8 weeks	66	38	36
Phase III 12 weeks	Asthma	10	12 weeks	4 weeks	28	12	10
Phase III 24 weeks	Asthma	20	24 weeks	8 weeks	49	25	20
Phase III 32 weeks	Asthma	80	24 weeks	12 weeks	88	80	74
Phase III 6 weeks	Asthma	20	6 weeks	2 weeks	22	20	20
Phase III 16 weeks	Asthma	40	16 weeks	3 weeks	50	40	35
Phase III 12 weeks	Asthma	80	12 weeks	6 weeks	85	69	69
Phase IV 8 weeks	Asthma	40	8 weeks	6 weeks	40	35	35
Phase IV 8 weeks	Asthma	35	8 weeks	3 weeks	50	35	35
Phase IV 8 weeks	COPD	50	12 weeks	8 weeks	69	54	48
Phase III 15 weeks	COPD	20	12 weeks	7 weeks	33	19	17
Phase III 2 weeks	COPD	20	12 weeks	4 weeks	34	31	31
Therapeutic equivalence 6 weeks	Asthma	12	4 weeks	2 weeks	27	21	21
Therapeutic equivalence 6 weeks	Asthma	16	4 weeks	2 weeks	31	28	26
Inhalation Behavior Study 2 weeks	Asthma	24	2 weeks	1 week	24	24	24